 Novan, Inc. is a late-clinical-stage biotechnology company specializing in therapeutics based on nitric oxides naturally occurring anti-viral, anti-bacterial, anti-fungal, and immunomodulatory mechanisms of action. Novan has a pipeline of 6 NO-based therapeutics with 5 in the clinical stage; however, after limited funding, Novan announced a 2021 pause on other trials until SB206s Phase 3 Q2-results. 